

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/082719 A1

- (51) International Patent Classification⁷: **A61K 47/44**, 45/06
- (74) Agents: **LUMB, J., Trevor et al.**; Pfizer Inc., P.O. Box 1027, St. Louis, MO 63006 (US).
- (21) International Application Number:
PCT/IB2004/000802
- (22) International Filing Date: 10 March 2004 (10.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/456,201 20 March 2003 (20.03.2003) US
- (71) Applicant (for all designated States except US): **PHARMACIA CORPORATION** [US/US]; 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BRITTEN, Nancy, J.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **BURNS, John, W.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **HALLBERG, John, W.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **WALDRON, Niki, A.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **WATTS, Jeffrey, L.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS

(57) Abstract: A method is provided for treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy with the antibacterial agent a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent and, optionally, the second agent, are administered as a pharmaceutical composition further comprising a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insoluble, microcrystalline wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the antibacterial agent and the second agent. The composition is readily dispersible in the fluid of the fluid-containing organ.



WO 2004/082719 A1